+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Teneligliptin Hydrobromide Tablet Market - Global Forecast 2025-2030- Product Image
Teneligliptin Hydrobromide Tablet Market - Global Forecast 2025-2030- Product Image
Sale

Teneligliptin Hydrobromide Tablet Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6078641
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Teneligliptin Hydrobromide tablets market is evolving rapidly as healthcare systems intensify their focus on innovative solutions for type 2 diabetes management. Senior stakeholders face growing challenges to improve outcomes, meet regulatory demands, and support cost-conscious strategies while enabling patient-friendly treatment options. Decision-makers must navigate dynamic supply chains, competitive differentiation, and shifting reimbursement models to drive sustainable growth in this high-potential segment.

Market Snapshot: Teneligliptin Hydrobromide Tablets

The global Teneligliptin Hydrobromide tablets market demonstrates significant growth momentum, driven by the increasing prevalence of chronic metabolic conditions and a marked demand for DPP-4 inhibitors with favorable safety profiles. Notably, recent advances in oral formulation technology are enhancing both patient adherence and clinical appeal. Regulatory shifts in key geographies are broadening use-case scenarios—especially within combination therapy regimens—allowing this therapeutic class to further penetrate institutional and outpatient care settings. The evolving payer landscape, combined with regional trends in access expansion, signals an environment ripe for innovation and portfolio diversification.

Scope & Segmentation

This research report provides a comprehensive analysis of the Teneligliptin Hydrobromide market, covering multiple operational and geographic fronts. Insights are organized across essential segmentation categories and geographic regions to inform strategy development:

  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy
  • End Users: Clinics (general clinics, specialty clinics), home care, hospitals (primary, secondary, tertiary)
  • Product Types: Branded, generic
  • Therapy Modes: Combination therapy (insulin, metformin, sulfonylurea combinations), monotherapy
  • Treatment Durations: Less than three months, more than six months, three to six months
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Participants: Mitsubishi Tanabe Pharma Corporation, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Dr. Reddy’s Laboratories, Hetero Drugs, Lupin, Cipla, Aurobindo Pharma, Sun Pharma, Alembic Pharmaceuticals

Key Takeaways for Senior Decision-Makers

  • Teneligliptin Hydrobromide tablets deliver a unique pharmacokinetic profile that supports once-daily dosing, minimizing patient burden and supporting real-world adherence initiatives.
  • Technological innovations in oral formulation and fixed-dose combinations are enhancing bioavailability and enabling tailored therapy regimens across diverse patient populations.
  • Regulatory agencies are expediting review pathways and encouraging outcome data submissions, influencing both branded and generic manufacturer strategies for portfolio expansion.
  • Competitors employ process scale-up, digital health partnerships, and collaborative alliances to accelerate market penetration and support evidence generation initiatives.
  • Emerging markets and regional variations, especially in Asia-Pacific and Latin America, are key growth drivers due to high diabetes prevalence and progressive reimbursement policies.
  • Segmentation insights allow companies to optimize channel partnerships, invest in adherence support, and capture value via differentiated products tailored to local market dynamics.

Tariff Impact on Supply Chains and Cost Structure

U.S. tariff adjustments implemented in early 2025 have introduced cumulative cost pressures throughout the Teneligliptin Hydrobromide supply chain. Manufacturers reliant on overseas active pharmaceutical ingredients are turning to near-shoring and diversified sourcing strategies to maintain operational resilience. These tariffs influence contract terms with payers and require robust pharmacoeconomic evidence during pricing negotiations. Industry players are collaborating across API production and domestic manufacturing to mitigate supply disruptions and safeguard patient access.

Research Methodology & Data Sources

This study integrates extensive secondary research—spanning peer-reviewed journals, regulatory filings, and company reports—with structured primary interviews involving endocrinologists, pharmacists, payers, and thought leaders in key regions. Data triangulation and validation with subject matter experts ensure practical, actionable insights. Strict confidentiality and ethical protocols were maintained throughout data collection.

Why This Report Matters

  • Facilitates evidence-based planning and portfolio differentiation by presenting actionable intelligence across the full Teneligliptin Hydrobromide value chain.
  • Empowers organizations to proactively address regulatory, supply chain, and competitive risks, while maximizing market access opportunities in growth geographies.
  • Enables tailored investment and channel strategies through detailed segmentation and regional insight analysis.

Conclusion

Teneligliptin Hydrobromide tablets continue to redefine the DPP-4 inhibitor segment by aligning with stakeholder demands for patient-centric, value-driven solutions. Adaptability to regulatory changes, technological innovation, and regional variations is essential for sustained market success.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of fixed dose combinations of teneligliptin with SGLT2 inhibitors in type 2 diabetes therapy
5.2. Expansion of teneligliptin hydrobromide tablet generics following key patent expirations in major pharmaceutical markets
5.3. Strategic licensing agreements accelerating teneligliptin distribution across emerging markets such as Latin America and Africa
5.4. Comparative clinical studies highlighting improved glycaemic control and cardiovascular safety profile of teneligliptin in high-risk patients
5.5. Pricing pressures from biosimilar and generic entrants reshaping teneligliptin market dynamics in Europe and Asia-Pacific
5.6. Investment in local manufacturing facilities enhancing teneligliptin supply chain resilience and cost efficiencies in India
5.7. Integration of digital health platforms to monitor patient adherence and outcomes with teneligliptin hydrobromide therapy in outpatient settings
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Teneligliptin Hydrobromide Tablet Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Teneligliptin Hydrobromide Tablet Market, by End User
9.1. Introduction
9.2. Clinics
9.2.1. General Clinics
9.2.2. Specialty Clinics
9.3. Home Care
9.4. Hospitals
9.4.1. Primary Hospitals
9.4.2. Secondary Hospitals
9.4.3. Tertiary Hospitals
10. Teneligliptin Hydrobromide Tablet Market, by Product Type
10.1. Introduction
10.2. Branded
10.3. Generic
11. Teneligliptin Hydrobromide Tablet Market, by Therapy Mode
11.1. Introduction
11.2. Combination Therapy
11.2.1. Insulin Combination
11.2.2. Metformin Combination
11.2.3. Sulfonylurea Combination
11.3. Monotherapy
12. Teneligliptin Hydrobromide Tablet Market, by Treatment Duration
12.1. Introduction
12.2. Less Than Three Months
12.3. More Than Six Months
12.4. Three To Six Months
13. Americas Teneligliptin Hydrobromide Tablet Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Teneligliptin Hydrobromide Tablet Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Teneligliptin Hydrobromide Tablet Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Mitsubishi Tanabe Pharma Corporation
16.3.2. Glenmark Pharmaceuticals Limited
16.3.3. Torrent Pharmaceuticals Limited
16.3.4. Dr. Reddy’s Laboratories Limited
16.3.5. Hetero Drugs Limited
16.3.6. Lupin Limited
16.3.7. Cipla Limited
16.3.8. Aurobindo Pharma Limited
16.3.9. Sun Pharmaceutical Industries Limited
16.3.10. Alembic Pharmaceuticals Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET: RESEARCHAI
FIGURE 26. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET: RESEARCHSTATISTICS
FIGURE 27. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET: RESEARCHCONTACTS
FIGURE 28. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRIMARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRIMARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY INSULIN COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY INSULIN COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY METFORMIN COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY METFORMIN COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY SULFONYLUREA COMBINATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY SULFONYLUREA COMBINATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY LESS THAN THREE MONTHS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY LESS THAN THREE MONTHS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY MORE THAN SIX MONTHS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY MORE THAN SIX MONTHS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THREE TO SIX MONTHS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THREE TO SIX MONTHS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 108. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 109. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 110. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 111. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 112. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 113. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 114. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 115. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 116. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 117. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 118. CANADA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 119. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 131. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 132. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 133. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 134. MEXICO TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 201. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 210. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 211. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 212. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 213. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 214. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 215. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 216. GERMANY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 217. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 228. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 229. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 230. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 231. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 232. FRANCE TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 249. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 254. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 255. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 256. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 257. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 258. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 259. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 260. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 261. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 262. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 263. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 264. ITALY TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 265. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 274. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 275. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 276. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 277. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 278. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 279. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2018-2024 (USD MILLION)
TABLE 280. SPAIN TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DURATION, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY THERAPY MODE, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES TENELIGLIPTIN HYDROBROMIDE TABLET MARKET SIZE, BY TREATMENT DU

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Teneligliptin Hydrobromide Tablet market report include:
  • Mitsubishi Tanabe Pharma Corporation
  • Glenmark Pharmaceuticals Limited
  • Torrent Pharmaceuticals Limited
  • Dr. Reddy’s Laboratories Limited
  • Hetero Drugs Limited
  • Lupin Limited
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Limited
  • Alembic Pharmaceuticals Limited

Related Topics

Related Reports

Teneligliptin Hydrobromide API Market - Global Forecast 2025-2030 - Product Image

Teneligliptin Hydrobromide API Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Olaparib Tablets Market - Global Forecast 2025-2030 - Product Image

Olaparib Tablets Market - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Imipramine Hydrochloride Tablet Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

Imipramine Hydrochloride Tablet Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 74 Pages
  • Global
From
Mercaptopurine Tablet Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Mercaptopurine Tablet Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Acetazolamide Tablet Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Acetazolamide Tablet Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.